

| Numéro de catalogue | HB941176 |
|---|---|
| Description |
Anti-Human VEGFA (GP2019) (HB941176) is a research-grade recombinant antibody targeting Vascular endothelial growth factor A. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Reactivité des espèces | Human |
| Applications | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| Espèce hôte | Human |
| Clonalité | Monoclonal |
| Isotype | IgG |
| ID de clone | GP2019 |
| Cible | L-VEGF, N-VEGF, VEGF, VEGFA, VPF, Vascular endothelial growth factor A, long form, Vascular permeability factor |
| Niveau d'endotoxines | < 10 EU/mg |
| Pureté | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Numéro d'accès | P15692 |
| Forme | Liquid |
| Tampon de stockage | 0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot. |
| Stabilité et stockage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Noms alternatifs | GP2019 |
| Contexte | Vascular endothelial growth factor A, long form (VEGFA) is a ~43 kDa protein. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death. VEGFA is the therapeutic target of bevacizumab (Avastin). 1. Katsman, M. et al. (2022) Cells 11. PMID: 35455969 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human VEGFA (GP2019)




Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.
Courrier : [email protected]


+86-027-65523339
Bâtiment C, No. 666, Rue Shendunsi, Wuhan, 430206, Chine
中文
English
한국어
日本語
Español
Français
Русский